<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089362</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01455</org_study_id>
    <secondary_id>04-053</secondary_id>
    <secondary_id>MSKCC-04053</secondary_id>
    <secondary_id>NCI-6542</secondary_id>
    <secondary_id>CDR0000378288</secondary_id>
    <secondary_id>U01CA069856</secondary_id>
    <nct_id>NCT00089362</nct_id>
  </id_info>
  <brief_title>Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride&#xD;
      in treating patients with metastatic or unresectable solid tumors. Drugs used in&#xD;
      chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxic effects and maximum tolerated dose of&#xD;
      17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in patients with metastatic or&#xD;
      unresectable solid tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      II. Determine the effects of this drug on the expression of Hsp90 client proteins in normal&#xD;
      and tumor tissue samples from these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride&#xD;
      until at least 1 of 2 patients experience dose-limiting toxicity (DLT). Cohorts are then&#xD;
      expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin&#xD;
      hydrochloride until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is&#xD;
      determined, 10 additional patients are treated at that dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Adenoid Cystic Carcinoma of the Oral Cavity</condition>
  <condition>Recurrent Basal Cell Carcinoma of the Lip</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Gastric Cancer</condition>
  <condition>Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Recurrent Lymphoepithelioma of the Oropharynx</condition>
  <condition>Recurrent Melanoma</condition>
  <condition>Recurrent Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <condition>Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Mucoepidermoid Carcinoma of the Oral Cavity</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Recurrent Salivary Gland Cancer</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Verrucous Carcinoma of the Larynx</condition>
  <condition>Recurrent Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage III Adenoid Cystic Carcinoma of the Oral Cavity</condition>
  <condition>Stage III Basal Cell Carcinoma of the Lip</condition>
  <condition>Stage III Colon Cancer</condition>
  <condition>Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage III Gastric Cancer</condition>
  <condition>Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage III Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Stage III Lymphoepithelioma of the Oropharynx</condition>
  <condition>Stage III Melanoma</condition>
  <condition>Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage III Mucoepidermoid Carcinoma of the Oral Cavity</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage III Renal Cell Cancer</condition>
  <condition>Stage III Salivary Gland Cancer</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage III Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage III Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Adenoid Cystic Carcinoma of the Oral Cavity</condition>
  <condition>Stage IV Basal Cell Carcinoma of the Lip</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Gastric Cancer</condition>
  <condition>Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Stage IV Lymphoepithelioma of the Oropharynx</condition>
  <condition>Stage IV Melanoma</condition>
  <condition>Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Mucoepidermoid Carcinoma of the Oral Cavity</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <condition>Stage IV Salivary Gland Cancer</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IV Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Untreated Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <arm_group>
    <arm_group_label>Treatment (alvespimycin hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvespimycin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvespimycin hydrochloride)</arm_group_label>
    <other_name>17-DMAG HCL</other_name>
    <other_name>KOS-1022</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (alvespimycin hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (alvespimycin hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor, including, but not limited to, the following:&#xD;
&#xD;
               -  Prostate&#xD;
&#xD;
               -  Breast&#xD;
&#xD;
               -  Ovary&#xD;
&#xD;
               -  Colon&#xD;
&#xD;
               -  Kidney&#xD;
&#xD;
               -  Head and neck&#xD;
&#xD;
               -  Stomach&#xD;
&#xD;
               -  Melanoma&#xD;
&#xD;
          -  Metastatic or unresectable disease&#xD;
&#xD;
          -  No standard curative or palliative therapy exists or is no longer effective&#xD;
&#xD;
          -  Progressive disease as indicated by the following:&#xD;
&#xD;
               -  Non-prostate cancer&#xD;
&#xD;
                    -  New lesions or increase in pre-existing lesions on bone scintigraphy, CT&#xD;
                       scan, MRI, or by physical examination&#xD;
&#xD;
                    -  No increase in biochemical markers (e.g., carcinoembryonic antigen or&#xD;
                       CA-15-3) or symptoms as sole evidence of disease progression&#xD;
&#xD;
               -  Prostate cancer&#xD;
&#xD;
                    -  Must have castrate metastatic disease (i.e., disease progression after&#xD;
                       castration or treatment with a gonadotropin-releasing hormone [GnRH] analog)&#xD;
&#xD;
                         -  Patients who have not undergone surgical orchiectomy must continue with&#xD;
                            medical therapy (i.e., GnRH analogs) to maintain castrate levels of&#xD;
                            serum testosterone &lt; 50 ng/dL&#xD;
&#xD;
                         -  Patients who received an antiandrogen as part of first-line hormonal&#xD;
                            therapy must show disease progression after discontinuing treatment&#xD;
&#xD;
                    -  Progressive metastatic disease on imaging studies (e.g., bone scan, CT scan,&#xD;
                       or MRI) OR metastatic disease and a rising prostate-specific antigen (PSA)&#xD;
                       allowed&#xD;
&#xD;
                         -  Biochemical progression is defined as a minimum of 3 rising PSA values&#xD;
                            from baseline obtained at least 1 week apart OR 2 rising PSA values&#xD;
                            obtained more than 1 month apart, with &gt;= 25% increase in value&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
          -  WBC &gt;= 3, 000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1, 500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 1.5 times ULN&#xD;
&#xD;
          -  PT normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.4 mg/dL&#xD;
&#xD;
          -  Creatinine clearance &gt; 55 mL/min&#xD;
&#xD;
          -  QTc &lt; 450 msec for male patients (470 msec for female patients)&#xD;
&#xD;
          -  LVEF &gt; 40% by MUGA&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or&#xD;
             ventricular fibrillation &gt;= 3 beats in a row)&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No active ischemic heart disease within the past year&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No congenital long QT syndrome&#xD;
&#xD;
          -  No left bundle branch block&#xD;
&#xD;
          -  No poorly controlled angina&#xD;
&#xD;
          -  No history of uncontrolled dysrhythmias or requiring antiarrhythmic drugs&#xD;
&#xD;
               -  Calcium blockers and beta blockers allowed&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
          -  Oxygen saturation &gt; 88%&#xD;
&#xD;
          -  Dyspnea &lt; grade 2 at rest on room air&#xD;
&#xD;
          -  No clinically significant pulmonary comorbidity (e.g., severe chronic obstructive&#xD;
             pulmonary disease)&#xD;
&#xD;
          -  No requirement for supplemental oxygen&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy &gt;= grade 2&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas)&#xD;
&#xD;
          -  At least 1 week since prior ketoconazole&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 4 weeks since prior investigational anticancer therapeutic drugs&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent administration of any of the following herbal remedies:&#xD;
&#xD;
               -  Hydrastis canadensis (goldenseal)&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Uncaria tomentosa (cat's claw)&#xD;
&#xD;
               -  Echinacea angustifolia roots&#xD;
&#xD;
               -  Trifolium pratense (wild cherry)&#xD;
&#xD;
               -  Matricaria chamomilla (chamomile)&#xD;
&#xD;
               -  Glycyrrhiza glabra (licorice)&#xD;
&#xD;
               -  Dillapiol&#xD;
&#xD;
               -  Hypericin&#xD;
&#xD;
               -  Naringenin&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Solit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
    <mesh_term>Carcinoma, Mucoepidermoid</mesh_term>
    <mesh_term>Esthesioneuroblastoma, Olfactory</mesh_term>
    <mesh_term>Papilloma, Inverted</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
    <mesh_term>Granuloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

